[1] Venkataramana K.Sidhaye,Kristine Nishida,Fernando J.Martinez.Precision medicine
in COPD: where are we and where do we need to go? [J]. Eur Respir Rev, 2018, 27(149):
180022.
[2] Antonino Di Stefano,Teresa Coccini,Elisa Roda,et al.Blood MCP-1 levels are increased in chronic obstructive pulmonary disease patients
with prevalent emphysema [J]. International Journal of Chronic Obstructive Pulmonary
Disease, 2018, 13:1691-700.
[3] Martinez FJ,Han MK,Allinson JP,et al.At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary
Disease [J]. American Journal of Respiratory and Critical Care Medicine, 2018, 197(12):
1540-51.
[4]Miravitlles M,Soler-Cataluña JJ,Calle M,et al. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease(GesEPOC)2017.Pharmacological
Treatment of Stable Phase [J]. Arch Bronconeumol, 2017, 53(6): 324-35.
[5] Kania A,Krenke R,Kuziemski K,et al. Distribution and characteristics of COPD phenotypes-results from the Polish sub-cohort
of the POPE study [J]. International Journal of Chronic Obstructive Pulmonary Disease,
2018, 13:1613-21.
[6]Reiger G,Zwick R,Lamprecht B,et al. Phenotypes of COPD in an Austrian population: National data from the POPE study
[J]. Wiener Klinische Wochenschrift, 2018, 130(11-12): 382-9.
[7]Alcázar-Navarrete Bernardino,Trigueros Juan Antonio,Riesco Juan Antonio,et al. Geographic
variations of the prevalence and distribution of COPD phenotypes in Spain: “the ESPIRAL-ES
study” [J]. Oxidative Medicine and Cellular Longevity, 2018, 13:1115-24.
[8]Alcázar-Navarrete B,Romero-Palacios PJ,Ruiz-Sancho A,et al. Diagnostic performance
of the measurement of nitric oxide in exhaled air in the diagnosis of COPD phenotypes
[J]. Nitric Oxide - Biology and Chemistry, 2016, 54:67-72.
[9]Alexandru Corlateanu,Victor Botnaru,Doina Rusu, et al. Assessment of health-related
quality of life in different phenotypes of COPD [J]. Current Respiratory Medicine
Reviews, 2017, 13(2): 105-9.
[10]Cosio BG,Soriano JB,López-Campos JL,et al. Correction: Distribution and Outcomes of
a Phenotype-Based Approach to Guide COPD Management: Results from the CHAIN Cohort
[J]. PLoS ONE, 2016, 11 (9):e0160770.
[11]Golpe R,Suárez-Valor M,Martín-Robles I,et al. Mortality in COPD patients according
to clinical phenotypes [J]. International Journal of Chronic Obstructive Pulmonary
Disease, 2018, 13:1433-9.
[12]Koblizek V,Milenkovic B,Barczyk A,et al. Phenotypes of COPD patients with a smoking
history in Central and Eastern Europe: the POPE Study [J]. The European Respiratory
Journal, 2017, 49(5):1601446.
[13]Miravitlles M,Barrecheguren M,Román-Rodríguez M. Frequency and characteristics of
different clinical phenotypes of chronic obstructive pulmonary disease [J]. International
Journal of Tuberculosis and Lung Disease, 2015, 19(8): 992-8.
[14]Arkhipov V,Arkhipova D,Miravitlles M,et al. Characteristics of COPD patients according
to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT
trial [J]. International Journal of Chronic Obstructive Pulmonary Disease, 2017, 12:3255-62.
[15] Chee-Shee Chai,Chong-Kin Liam,Yong-Kek Pang,et al. Clinical phenotypes of COPD and
health-related quality of life: a cross-sectional study [J]. International Journal
of COPD, 2019, 14:565-73.
[16]Pan Qing,Lv Zhifang.clinical application value of the new guide patients with chronic
obstructive pulmonary disease. [J]. Journal of shandong university(health sciences),
2016, 54(3): 63-7.
[17]
Calle Rubio M,Casamor R,Miravitlles M. Identification and distribution of COPD phenotypes
in clinical practice according to Spanish COPD Guidelines: the FENEPOC study [J].
International Journal of Chronic Obstructive Pulmonary Disease, 2017, 12:2373-83.
[18]
Begg CB,Mazumdar M. Operating characteristics of a rank correlation test for publication
bias [J]. Biometrics, 1994, 50(4): 1088-101.
[19]Harbord RM,Egger M,Sterne JA. A modified test for small-study effects in meta-analyses
of controlled trials with binary endpoints [J]. Stat Med, 2006, 25(20): 3443-57.
[20]Windisch W,Criée CP.COPD-Importance of Lung Function Testing for Diagnosis and Treatment[J].Dtsch
Med Wochenschr.2018,143(8):593-596.
[21]Lei Zhu,Lijuan Hu,Li li,et al. Suggestions on diagnosis of pulmonary function [J].
Chin J Tubere Respir Dis, 2018, 41(4): 308-11.
[22]Augustin IML,Wouters EFM,Houben-Wilke S,et al. Comprehensive Lung Function Assessment
Does not Allow to Infer Response to Pulmonary Rehabilitation in Patients with COPD.
[J]. J Clin Med, 2019, 8(1): pii:E27.
[23] GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global
Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. ; 2018 (https://goldcoped.org/. Accessed July 17, 2018).
[24]Umur Hatipoğlu. Chronic obstructive pulmonary disease:More than meets the eye [J].
Annals of Thoracic Medicine, 2018, 13(1): 1-6.
[25]Magnus MC1,Henderson J,Tilling K,et al. Independent and combined associations of maternal
and own smoking with adult lung function and COPD [J]. Int J Epidemiol, 2018, 47(6):
1855-64.
[26]Cheng SL,Lin CH,Wang CC,et al. Comparison between COPD Assessment Test (CAT) and modified
Medical Research Council (mMRC) dyspnea scores for evaluation of clinical symptoms,
comorbidities and medical resources utilization in COPD patients [J]. J Formos Med
Assoc, 2019, 118(1 Pt 3): 429-35.
[27]Grigsby MR1,Siddharthan T,Pollard SL,et al. Low Body Mass Index Is Associated with
Higher Odds of COPD and Lower Lung Function in Low- and Middle-Income Countries [J].
Copd, 2019, 16(1) 58-65.